"Epcoritamab and R 2 is a novel chemotherapy-free fixed-duration therapy that is suitable for outpatient administration and, we believe, sets a new benchmark as a standard of care for second-line [or ...

"One of the most serious public health challenges of our time." -- World Health Organization Director-General Tedros Adhanom ...

Early Alzheimer's patients who completed their course of donanemab therapy by 12 months had cognitive and functional benefits lasting for 2 additional years, reported Jennifer Zimmer, MD, of Eli Lilly ...

HHS is tasked with communicating information to protect and improve the health and well-being of every American. It provides ...

Patients with <7/8 transplants had a 1-year survival of 85.6% versus 78.6% for those who received better-matched donor cells.

A conditioning regimen free from total body irradiation (TBI) appeared to be just as effective as standard of care (SoC) in a ...

They don't seek medical care first, but find solace in stories and role models who seem to "get it." But often, the ...

The aim of the fixed-duration approach is to "produce deep remissions and thereby allow patients to get off therapy while ...

The White House released a physician memo stating that President Trump received advanced imaging to assess his cardiovascular ...

Neflamapimod is an oral p38 alpha kinase inhibitor that targets dysfunction and degeneration of acetylcholine-producing ...

ATLANTA -- In health matters it's not often that older people do better than their younger peers, but seizure disorders may be an example, suggested a cross-sectional study.